TIL expansion processes using specific cytokine combinations and/or AKTi treatment
US11981921B2 · kind B2 · utility
0Cited by
186References
29Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 20, 2023 |
| Grant date | May 14, 2024 |
| Priority date | — |
| Expiry date | Jun 20, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein are methods of producing TILs via (i) pre-REP stimulation with a combination of interferon gamma (IFNγ) and an anti-PD-1 antibody, with or without a CD40 agonist, and with or without an anti-CTLA-4 antibody (ii) various concentrations of IL-15 and IL-21, with or without low-concentration IL-2, with or without an AKT inhibitor (AKTi) during REP expansion and/or pre-REP expansion, (iii) low-concentration IL-2 and an AKTi during REP expansion and/or pre-REP expansion, (iv) the combination of (i) and (ii), or (v) the combination of (i) and (iii).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.